Tavexia Lifecare
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Tavexia Lifecare approved the acquisition of 60% of Meyonex Pharmaceuticals through subscription to 2,09,97,180 fresh equity shares at Rs 32 each for total cash consideration of Rs 67.19 crore. The subscription would take Meyonex's equity base to 3,49,95,300 shares, with Tavexia holding 60% and existing shareholders retaining 40%. Meyonex, an unlisted Indian pharmaceutical company incorporated in 2015, reported turnover of around Rs 10.79 crore in FY25 and Rs 13.32 crore in FY24. The investment was to be completed in one or more tranches subject to shareholder and regulatory approvals and definitive agreements, with funding planned through a future preferential or rights issue of securities.
Powered by Tijori
Tavexia Lifecare approved the acquisition of 60% of Meyonex Pharmaceuticals through subscription to 2,09,97,180 fresh equity shares at Rs 32 each for total cash consideration of Rs 67.19 crore. The subscription would take Meyonex's equity base to 3,49,95,300 shares, with Tavexia holding 60% and existing shareholders retaining 40%. Meyonex, an unlisted Indian pharmaceutical company incorporated in 2015, reported turnover of around Rs 10.79 crore in FY25 and Rs 13.32 crore in FY24. The investment was to be completed in one or more tranches subject to shareholder and regulatory approvals and definitive agreements, with funding planned through a future preferential or rights issue of securities.
Powered by Tijori
Tavexia Lifecare's board approved the proposed acquisition of a 60% stake in unlisted Meyonex Pharmaceuticals through subscription to 2.10 crore new shares at ₹32 each, implying a cash investment of ₹67.19 crore. The transaction remained subject to definitive agreements and applicable shareholder, statutory and regulatory approvals, while the board also approved in principle a future equity or debt fund raise to finance it; Meyonex reported turnover of ₹13.32 crore in FY2024 and ₹10.79 crore in FY2025.
Powered by Tijori
Tavexia Lifecare's board approved the proposed acquisition of a 60% stake in unlisted Meyonex Pharmaceuticals through subscription to 2.10 crore new shares at ₹32 each, implying a cash investment of ₹67.19 crore. The transaction remained subject to definitive agreements and applicable shareholder, statutory and regulatory approvals, while the board also approved in principle a future equity or debt fund raise to finance it; Meyonex reported turnover of ₹13.32 crore in FY2024 and ₹10.79 crore in FY2025.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 2,50,000 equity shares in an on-market transaction on 28 September 2026. Its holding fell from 1,41,60,794 shares to 1,39,10,794 shares, while the combined holding with Puja Agarwal declined from 1,42,40,794 shares, or 3.713%, to 1,39,90,794 shares, or 3.647%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 2,50,000 equity shares in an on-market transaction on 28 September 2026. Its holding fell from 1,41,60,794 shares to 1,39,10,794 shares, while the combined holding with Puja Agarwal declined from 1,42,40,794 shares, or 3.713%, to 1,39,90,794 shares, or 3.647%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 7,00,000 equity shares in an on-market transaction on 25 September 2026. Its holding fell from 1,48,60,794 shares to 1,41,60,794 shares, while the combined holding with Puja Agarwal declined from 1,49,40,794 shares, or 3.895%, to 1,42,40,794 shares, or 3.713%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 7,00,000 equity shares in an on-market transaction on 25 September 2026. Its holding fell from 1,48,60,794 shares to 1,41,60,794 shares, while the combined holding with Puja Agarwal declined from 1,49,40,794 shares, or 3.895%, to 1,42,40,794 shares, or 3.713%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 2,00,000 equity shares in an on-market transaction on 24 September 2026. Its holding fell from 1,50,60,794 shares to 1,48,60,794 shares, while the combined holding with Puja Agarwal declined from 1,51,40,794 shares, or 3.947%, to 1,49,40,794 shares, or 3.895%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 2,00,000 equity shares in an on-market transaction on 24 September 2026. Its holding fell from 1,50,60,794 shares to 1,48,60,794 shares, while the combined holding with Puja Agarwal declined from 1,51,40,794 shares, or 3.947%, to 1,49,40,794 shares, or 3.895%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 4,00,000 equity shares in an on-market transaction on 23 September 2026. Its holding fell from 1,54,60,794 shares to 1,50,60,794 shares, while the combined holding with Puja Agarwal declined from 1,55,40,794 shares, or 4.051%, to 1,51,40,794 shares, or 3.947%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 4,00,000 equity shares in an on-market transaction on 23 September 2026. Its holding fell from 1,54,60,794 shares to 1,50,60,794 shares, while the combined holding with Puja Agarwal declined from 1,55,40,794 shares, or 4.051%, to 1,51,40,794 shares, or 3.947%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 9,07,105 equity shares in an on-market transaction on 21 September 2026. Its holding fell from 1,63,67,899 shares to 1,54,60,794 shares, while the combined holding with Puja Agarwal declined from 1,64,47,899 shares, or 4.288%, to 1,55,40,794 shares, or 4.051%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 9,07,105 equity shares in an on-market transaction on 21 September 2026. Its holding fell from 1,63,67,899 shares to 1,54,60,794 shares, while the combined holding with Puja Agarwal declined from 1,64,47,899 shares, or 4.288%, to 1,55,40,794 shares, or 4.051%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 2,80,000 equity shares in an on-market transaction on 18 September 2026. Its holding fell from 1,66,47,899 shares to 1,63,67,899 shares, while the combined holding with Puja Agarwal declined from 1,67,27,899 shares, or 4.36%, to 1,64,47,899 shares, or 4.288%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 2,80,000 equity shares in an on-market transaction on 18 September 2026. Its holding fell from 1,66,47,899 shares to 1,63,67,899 shares, while the combined holding with Puja Agarwal declined from 1,67,27,899 shares, or 4.36%, to 1,64,47,899 shares, or 4.288%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 10 lakh equity shares in an on-market transaction on 17 September 2026. Its holding fell from 1,76,47,899 shares to 1,66,47,899 shares, while the combined holding with Puja Agarwal declined from 1,77,27,899 shares, or 4.62%, to 1,67,27,899 shares, or 4.36%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 10 lakh equity shares in an on-market transaction on 17 September 2026. Its holding fell from 1,76,47,899 shares to 1,66,47,899 shares, while the combined holding with Puja Agarwal declined from 1,77,27,899 shares, or 4.62%, to 1,67,27,899 shares, or 4.36%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 8,01,878 equity shares in an on-market transaction on 16 September 2026. Its holding fell from 1,84,49,777 shares to 1,76,47,899 shares, while the combined holding with Puja Agarwal declined from 1,85,29,777 shares, or 4.83%, to 1,77,27,899 shares, or 4.62%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 8,01,878 equity shares in an on-market transaction on 16 September 2026. Its holding fell from 1,84,49,777 shares to 1,76,47,899 shares, while the combined holding with Puja Agarwal declined from 1,85,29,777 shares, or 4.83%, to 1,77,27,899 shares, or 4.62%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 14 lakh equity shares in an on-market transaction on 15 September 2026. Its holding fell from 1,98,49,777 shares to 1,84,49,777 shares, while the combined holding with Puja Agarwal declined from 1,99,29,777 shares, or 5.19%, to 1,85,29,777 shares, or 4.83%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 14 lakh equity shares in an on-market transaction on 15 September 2026. Its holding fell from 1,98,49,777 shares to 1,84,49,777 shares, while the combined holding with Puja Agarwal declined from 1,99,29,777 shares, or 5.19%, to 1,85,29,777 shares, or 4.83%, with paid-up capital unchanged at 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 18 lakh equity shares in an on-market transaction on 11 September 2026, reducing its holding from 2.1649 crore shares, or 5.66%, to 1.9849 crore shares, or 5.19%. The promoter group's total holding, including Puja Agarwal's 80,000 shares, fell by 0.47 percentage points, while Tavexia Lifecare's paid-up capital remained 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 18 lakh equity shares in an on-market transaction on 11 September 2026, reducing its holding from 2.1649 crore shares, or 5.66%, to 1.9849 crore shares, or 5.19%. The promoter group's total holding, including Puja Agarwal's 80,000 shares, fell by 0.47 percentage points, while Tavexia Lifecare's paid-up capital remained 38.36 crore shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 14 lakh shares, or 0.36% of the company, in an on-market transaction on 7 September 2026. Its holding fell from about 2.30 crore shares, or 6.02%, to about 2.16 crore shares, or 5.66%, while promoter-group associate Puja Agarwal retained 80,000 shares.
Powered by Tijori
Roshan Dealmark Private Limited, a promoter-group entity of Tavexia Lifecare, sold 14 lakh shares, or 0.36% of the company, in an on-market transaction on 7 September 2026. Its holding fell from about 2.30 crore shares, or 6.02%, to about 2.16 crore shares, or 5.66%, while promoter-group associate Puja Agarwal retained 80,000 shares.
Powered by Tijori
Tavexia Lifecare authorised a preliminary evaluation of a proposed acquisition of up to 60% of Meyonex Pharmaceuticals, an unlisted pharmaceutical company in Maharashtra. Two directors were empowered to conduct due diligence, valuation and negotiations, although no purchase price or binding transaction terms were disclosed. Meyonex had authorised capital of ₹20 crore and paid-up capital of about ₹14 crore. The board also accepted the immediate resignation of SSRV & Associates and proposed Devam & Associates LLP as statutory auditor, subject to shareholder approval.
Powered by Tijori
Tavexia Lifecare authorised a preliminary evaluation of a proposed acquisition of up to 60% of Meyonex Pharmaceuticals, an unlisted pharmaceutical company in Maharashtra. Two directors were empowered to conduct due diligence, valuation and negotiations, although no purchase price or binding transaction terms were disclosed. Meyonex had authorised capital of ₹20 crore and paid-up capital of about ₹14 crore. The board also accepted the immediate resignation of SSRV & Associates and proposed Devam & Associates LLP as statutory auditor, subject to shareholder approval.
Powered by Tijori
Roshan Dealmark Private Limited, part of Tavexia Lifecare's promoter group, sold 14 lakh equity shares in an on-market transaction on 3 September 2026. Its holding fell from 2.44 crore shares, or 6.39%, to 2.30 crore shares, or 6.02%, while person acting in concert Puja Agarwal retained 80,000 shares.
Powered by Tijori
Roshan Dealmark Private Limited, part of Tavexia Lifecare's promoter group, sold 14 lakh equity shares in an on-market transaction on 3 September 2026. Its holding fell from 2.44 crore shares, or 6.39%, to 2.30 crore shares, or 6.02%, while person acting in concert Puja Agarwal retained 80,000 shares.
Powered by Tijori
Aug 26 (Reuters) - Tavexia Lifecare Ltd TAVX.BO:
TAVEXIA LIFECARE- EXPANDS BUSINESS WITH ENTRY INTO PHARMACEUTICALS
Source text: ID:nnAZN4TGASU
Further company coverage: TAVX.BO
(([email protected];))
Aug 26 (Reuters) - Tavexia Lifecare Ltd TAVX.BO:
TAVEXIA LIFECARE- EXPANDS BUSINESS WITH ENTRY INTO PHARMACEUTICALS
Source text: ID:nnAZN4TGASU
Further company coverage: TAVX.BO
(([email protected];))
May 20 (Reuters) - Sattva Sukun Lifecare Ltd STTV.BO:
SATTVA SUKUN LIFECARE LTD - REPORTS CYBERSECURITY INCIDENT AT THIRD-PARTY SERVICE PROVIDER FOR EMAIL AND WEBSITE HOSTING
SATTVA SUKUN LIFECARE LTD - EMAIL SERVICES DISRUPTED AND WEBSITE TEMPORARILY UNAVAILABLE DUE TO INCIDENT
SATTVA SUKUN LIFECARE LTD - ATTACKER ALLEGEDLY DELETED DATABASE SERVER DATA AND HISTORICAL BACKUPS
SATTVA SUKUN LIFECARE LTD - CYBERATTACK ON SERVICE PROVIDER CAUSES UNAUTHORIZED ACCESS AND SEVERE DATA DAMAGE
SATTVA SUKUN LIFECARE LTD - IMPACT ON COMPANY'S DATA AND OPERATIONS IS BEING EVALUATED
Source text: ID:nBSE3C2rJD
Further company coverage: STTV.BO
(([email protected];))
May 20 (Reuters) - Sattva Sukun Lifecare Ltd STTV.BO:
SATTVA SUKUN LIFECARE LTD - REPORTS CYBERSECURITY INCIDENT AT THIRD-PARTY SERVICE PROVIDER FOR EMAIL AND WEBSITE HOSTING
SATTVA SUKUN LIFECARE LTD - EMAIL SERVICES DISRUPTED AND WEBSITE TEMPORARILY UNAVAILABLE DUE TO INCIDENT
SATTVA SUKUN LIFECARE LTD - ATTACKER ALLEGEDLY DELETED DATABASE SERVER DATA AND HISTORICAL BACKUPS
SATTVA SUKUN LIFECARE LTD - CYBERATTACK ON SERVICE PROVIDER CAUSES UNAUTHORIZED ACCESS AND SEVERE DATA DAMAGE
SATTVA SUKUN LIFECARE LTD - IMPACT ON COMPANY'S DATA AND OPERATIONS IS BEING EVALUATED
Source text: ID:nBSE3C2rJD
Further company coverage: STTV.BO
(([email protected];))
Nov 28 (Reuters) - Mayukh Dealtrade Ltd MAYK.BO:
MAYUKH DEALTRADE - GOT ORDER FOR 10,000 UNITS OF MAYUKH ELECTRIC KAPOOR DANI (WOODEN)
Further company coverage: MAYK.BO
(([email protected];))
Nov 28 (Reuters) - Mayukh Dealtrade Ltd MAYK.BO:
MAYUKH DEALTRADE - GOT ORDER FOR 10,000 UNITS OF MAYUKH ELECTRIC KAPOOR DANI (WOODEN)
Further company coverage: MAYK.BO
(([email protected];))
June 9 (Reuters) - Mayukh Dealtrade Ltd MAYK.BO:
APPROVED CONVERSION OF 100,000 WARRANTS INTO 100,000 EQUITY SHARES
APPROVED CONVERSION OF WARRANTS AT A PRICE OF 9.2 RUPEES PER SHARE
Source text for Eikon: ID:nBSE1XxxDf
Further company coverage: MAYK.BO
(([email protected];))
June 9 (Reuters) - Mayukh Dealtrade Ltd MAYK.BO:
APPROVED CONVERSION OF 100,000 WARRANTS INTO 100,000 EQUITY SHARES
APPROVED CONVERSION OF WARRANTS AT A PRICE OF 9.2 RUPEES PER SHARE
Source text for Eikon: ID:nBSE1XxxDf
Further company coverage: MAYK.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Tavexia Lifecare do?
Tavexia Lifecare Ltd. is building a diversified pharmaceutical platform spanning API marketing, finished formulations, CDMO, exports, nutraceuticals and clinical research, while continuing its existing lifecare business.
Who are the competitors of Tavexia Lifecare?
Tavexia Lifecare major competitors are Future Consumer, Danube Industries, Synoptics Techno., Simandhar Impex, ABM International, Ramgopal Polytex, Royal Sense. Market Cap of Tavexia Lifecare is ₹45 Crs. While the median market cap of its peers are ₹43 Crs.
Is Tavexia Lifecare financially stable compared to its competitors?
Tavexia Lifecare seems to be less financially stable compared to its competitors. Altman Z score of Tavexia Lifecare is 0.65 and is ranked 7 out of its 8 competitors.
Does Tavexia Lifecare pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Tavexia Lifecare latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Tavexia Lifecare allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory
How strong is Tavexia Lifecare balance sheet?
Tavexia Lifecare balance sheet is weak and might have solvency issues
Is the profitablity of Tavexia Lifecare improving?
The profit is oscillating. The profit of Tavexia Lifecare is -₹0.9 Crs for TTM, ₹2.49 Crs for Mar 2025 and ₹1.19 Crs for Mar 2024.
Is the debt of Tavexia Lifecare increasing or decreasing?
Yes, The net debt of Tavexia Lifecare is increasing. Latest net debt of Tavexia Lifecare is ₹2.1 Crs as of Mar-26. This is greater than Mar-25 when it was ₹0.47 Crs.
Is Tavexia Lifecare stock expensive?
Tavexia Lifecare is not expensive. Latest PE of Tavexia Lifecare is 0, while 3 year average PE is 72.49. Also latest EV/EBITDA of Tavexia Lifecare is 0.0 while 3yr average is 19.53.
Has the share price of Tavexia Lifecare grown faster than its competition?
Tavexia Lifecare has given better returns compared to its competitors. Tavexia Lifecare has grown at ~12.39% over the last 2yrs while peers have grown at a median rate of -12.0%
Is the promoter bullish about Tavexia Lifecare?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Tavexia Lifecare is 6.39% and last quarter promoter holding is 6.39%.
Are mutual funds buying/selling Tavexia Lifecare?
There is Insufficient data to gauge this.